Literature DB >> 27311820

Melanin and neuromelanin binding of drugs and chemicals: toxicological implications.

Oskar Karlsson1,2, Nils Gunnar Lindquist3.   

Abstract

Melanin is a polyanionic pigment that colors, e.g., the hair, skin and eyes. The pigment neuromelanin is closely related to melanin and is mainly produced in specific neurons of the substantia nigra. Certain drugs and chemicals bind to melanin/neuromelanin and are retained in pigment cells for long periods. This specific retention is thought to protect the cells but also to serve as a depot that slowly releases accumulated compounds and may cause toxicity in the eye and skin. Moreover, neuromelanin and compounds with high neuromelanin affinity have been suggested to be implicated in the development of adverse drug reactions in the central nervous system (CNS) as well as in the etiology of Parkinson's disease (PD). Epidemiologic studies implicate the exposure to pesticides, metals, solvents and other chemicals as risk factors for PD. Neuromelanin interacts with several of these toxicants which may play a significant part in both the initiation and the progression of neurodegeneration. MPTP/MPP(+) that has been casually linked with parkinsonism has high affinity for neuromelanin, and the induced dopaminergic denervation correlates with the neuromelanin content in the cells. Recent studies have also reported that neuromelanin may interact with α-synuclein as well as activate microglia and dendritic cells. This review aims to provide an overview of melanin binding of drugs and other compounds, and possible toxicological implications, with particular focus on the CNS and its potential involvement in neurodegenerative disorders.

Entities:  

Keywords:  ALS/PDC; BMAA; MPTP; Neuromelanin; Parkinson’s disease; Pesticides; Retinopathy

Mesh:

Substances:

Year:  2016        PMID: 27311820     DOI: 10.1007/s00204-016-1757-0

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  20 in total

1.  Creating a Simian Model of Guam ALS/PDC Which Reflects Chamorro Lifetime BMAA Exposures.

Authors:  Sandra Anne Banack; Paul Alan Cox
Journal:  Neurotox Res       Date:  2017-05-06       Impact factor: 3.911

Review 2.  Neuromelanin in Parkinson's Disease: from Fenton Reaction to Calcium Signaling.

Authors:  Rainer Knörle
Journal:  Neurotox Res       Date:  2017-09-06       Impact factor: 3.911

Review 3.  α-Synuclein in Parkinson's disease: causal or bystander?

Authors:  Peter Riederer; Daniela Berg; Nicolas Casadei; Fubo Cheng; Joseph Classen; Christian Dresel; Wolfgang Jost; Rejko Krüger; Thomas Müller; Heinz Reichmann; Olaf Rieß; Alexander Storch; Sabrina Strobel; Thilo van Eimeren; Hans-Ullrich Völker; Jürgen Winkler; Konstanze F Winklhofer; Ullrich Wüllner; Friederike Zunke; Camelia-Maria Monoranu
Journal:  J Neural Transm (Vienna)       Date:  2019-06-25       Impact factor: 3.575

4.  The Assessment of Meloxicam Phototoxicity in Human Normal Skin Cells: In Vitro Studies on Dermal Fibroblasts and Epidermal Melanocytes.

Authors:  Marta Karkoszka; Jakub Rok; Klaudia Banach; Justyna Kowalska; Zuzanna Rzepka; Dorota Wrześniok
Journal:  Molecules       Date:  2022-06-30       Impact factor: 4.927

5.  Neuromelanin organelles are specialized autolysosomes that accumulate undegraded proteins and lipids in aging human brain and are likely involved in Parkinson's disease.

Authors:  Fabio A Zucca; Renzo Vanna; Francesca A Cupaioli; Chiara Bellei; Antonella De Palma; Dario Di Silvestre; Pierluigi Mauri; Sara Grassi; Alessandro Prinetti; Luigi Casella; David Sulzer; Luigi Zecca
Journal:  NPJ Parkinsons Dis       Date:  2018-06-05

6.  The Presence of Alpha-Synuclein in Skin from Melanoma and Patients with Parkinson's Disease.

Authors:  Ildefonso Rodriguez-Leyva; Erika Chi-Ahumada; Manuel Mejía; Juan P Castanedo-Cazares; William Eng; Sami K Saikaly; Juan Carrizales; Todd D Levine; Robert A Norman; Maria E Jimenez-Capdeville
Journal:  Mov Disord Clin Pract       Date:  2017-06-01

Review 7.  Interaction of Neuromelanin with Xenobiotics and Consequences for Neurodegeneration; Promising Experimental Models.

Authors:  Andrea Capucciati; Fabio A Zucca; Enrico Monzani; Luigi Zecca; Luigi Casella; Tim Hofer
Journal:  Antioxidants (Basel)       Date:  2021-05-21

Review 8.  Imaging mass spectrometry in drug development and toxicology.

Authors:  Oskar Karlsson; Jörg Hanrieder
Journal:  Arch Toxicol       Date:  2016-12-08       Impact factor: 5.153

9.  Importance of Toxicokinetics to Assess the Utility of Zebrafish Larvae as Model for Psychoactive Drug Screening Using Meta-Chlorophenylpiperazine (mCPP) as Example.

Authors:  Krishna Tulasi Kirla; Ksenia J Groh; Michael Poetzsch; Rakesh Kumar Banote; Julita Stadnicka-Michalak; Rik I L Eggen; Kristin Schirmer; Thomas Kraemer
Journal:  Front Pharmacol       Date:  2018-04-26       Impact factor: 5.810

10.  Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.

Authors:  Toshiyuki Sakaeda; Shinji Kobuchi; Ryosuke Yoshioka; Mariko Haruna; Noriko Takahata; Yukako Ito; Aki Sugano; Kazuki Fukuzawa; Toshiki Hayase; Taro Hayakawa; Hideo Nakayama; Yutaka Takaoka; Masahiro Tohkin
Journal:  Int J Med Sci       Date:  2018-06-13       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.